COMMUNIQUÉS West-GlobeNewswire

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
12/01/2026
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN [...]
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
12/01/2026
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with [...]
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
12/01/2026
Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural [...]
AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies
12/01/2026
WILMINGTON, Del., Jan. 12, 2026 (GLOBE NEWSWIRE) -- AOP Health US, LLC announced today that Rapiblyk™ (landiolol) is now more widely available across the United States through Cardinal, Cencora Specialty Distribution, [...]
Helsinn announces new Executive Leadership Team as it celebrates 50 years
12/01/2026
Lugano, Switzerland – January 12th, 2026 – Helsinn Healthcare, a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, announces a new Executive Leadership Team as the company [...]
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
12/01/2026
The CGuard ® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- [...]
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
12/01/2026
Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenue MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of [...]
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
12/01/2026
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio’s Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families MENLO PARK, Calif., Jan. 12, 2026 (GLOBE [...]
Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025
12/01/2026
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended [...]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study
12/01/2026
Spear Bio joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation [...]
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
12/01/2026
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most [...]
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
12/01/2026
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that [...]
Acentra Health Honored as One of Modern Healthcare’s 2025 Best in Business
12/01/2026
The company earned recognition in the highly competitive Healthcare IT category for its configurable, modular solutions MCLEAN, Va., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions [...]
Press Release Biocartis NV: Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures
12/01/2026
PRESS RELEASE, 01/12/2026, 10:00 EST Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures Itasca, IL, US, 12 January 2026 – Biocartis announced today that it has entered into a research [...]
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
12/01/2026
Company to present at the 44th Annual JP Morgan Healthcare Conference FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced [...]
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
12/01/2026
Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and [...]
Teladoc Health Launches Enhanced 24/7 Care Service
12/01/2026
New capabilities enable Teladoc Health’s care teams to address a broader spectrum of health needs, delivering more value in virtual urgent care visits NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: [...]
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
12/01/2026
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan [...]
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
12/01/2026
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or [...]

Pages